FDA recommends continued use of Vytorin after review

01/8/2009 | CNNMoney · Bloomberg

The FDA backed continued use of Vytorin, a treatment from Merck & Co. and Schering-Plough, after concluding a safety review that found the drug more effective than generic medicine simvastatin in reducing "bad" cholesterol. The agency initiated an evaluation of Vytorin last year because of clinical-trial data showing that the medication was no better than simvastatin in clearing artery blockage.

View Full Article in:

CNNMoney · Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations